351185-23-4

Basic information

• Product Name: 2-aMino-4,7-dihydro-4-oxo-3H-Pyrrolo[2,3-d]pyriMidine-6-acetic acid
• Synonyms: 2-aMino-4,7-dihydro-4-oxo-3H-Pyrrolo[2,3-d]pyriMidine-6-acetic acid
• CAS NO: 351185-23-4
• Molecular Formula: C₈H₈N₄O₃
• Molecular Weight: 208.17412
• Mol File: 351185-23-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-aMino-4,7-dihydro-4-oxo-3H-Pyrrolo[2,3-d]pyriMidine-6-acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-aMino-4,7-dihydro-4-oxo-3H-Pyrrolo[2,3-d]pyriMidine-6-acetic acid(351185-23-4)
• EPA Substance Registry System: 2-aMino-4,7-dihydro-4-oxo-3H-Pyrrolo[2,3-d]pyriMidine-6-acetic acid(351185-23-4)

Safety Data

• Hazardous Substances Data: 351185-23-4(Hazardous Substances Data)

Upstream product

• 67226-39-5 (2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)acetic acid ethyl ester 
• 7355-55-7 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 

Downstream Products

• 1138038-51-3 8-{[3,5-bis(3,5-di-tert-butylbenzyloxy)benzylcarbamoyl]methyl}-7-deazaguanine 

Relevant articles and documents

Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase

A novel series of 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines were designed and synthesized as potential antitumor agents targeting both thymidylate and purine nucleotide biosynthesis. Starting from the key intermediate 2-amino-4-oxo-pyrrolo[2,3-d]pyrimidin-6-yl-acetic acid, target compounds 1–6 were successfully obtained through two sequential condensation and saponification reactions in decent yield. The newly synthesized compounds showed antiproliferative potencies against a panel of tumor cell lines including KB, SW620 and MCF7. In particular, most compounds of this series exhibited nanomolar to subnanomolar inhibitory activities toward KB tumor cells, significantly more potent than the positive control methotrexate (MTX) and pemetrexed (PMX). Along with the results of nucleoside protection assays, molecular modeling studies suggested that the antitumor activity of compound 6 could be attributed to multitargeted inhibition of folate-dependent enzymes thymidylate synthase (TS), glycinamide ribonucleotide formyltransferase (GARFTase) and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFTase). Growth inhibition by compound 6 also induced distinct early apoptosis and cell cycle arrest at S-phase, which resulted in cell death.

Pyrrolo [2, 3 - d] pyrimidine compounds and their use

The invention relates to a pyrrolo [2,3-d] pyrimidine compound, pharmaceutically acceptable salt thereof and a medicinal composition containing the pyrrolo [2,3-d] pyrimidine compound, and also relates to use of the pyrrolo [2,3-d] pyrimidine compound in preparation of a medicine for treating a disease related to GARFTase inhibition activity, in particularly relates to application of the pyrrolo [2,3-d] pyrimidine compound in preparation of an anti-cancer treatment medicine.